The law firm of Kirby McInerney LLP is investigating potential claims against Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT). The investigation concerns whether the Company...
Certara (NASDAQ:CERT) reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a...
RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter...
Barchart Research What to Expect from CERT Earnings CERT Generated May 8, 2026 Current Price $6.29 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 9.84% Certara's First Quarter Report Arrives...
Barchart Research What to Expect from CERT Earnings CERT Generated May 8, 2026 Current Price $6.29 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 9.84% Certara's First Quarter Report Arrives...
Barchart Research What to Expect from CERT Earnings CERT Generated May 8, 2026 Current Price $6.29 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 9.84% Certara's First Quarter Report Arrives...
Altasciences , a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed...
Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE...
RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first...
RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp ® Simulator enabled physiologically-based...